4.7 Article

Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study

Journal

INTERNATIONAL JOURNAL OF CANCER
Volume 128, Issue 10, Pages 2453-2462

Publisher

WILEY-BLACKWELL
DOI: 10.1002/ijc.25563

Keywords

bone metastases; integrins; osteolysis; volumetric computed tomography; dynamic contrast-enhanced MRI

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [SFB-TR23]
  2. Merck-Serono

Ask authors/readers for more resources

The aim of this study was to investigate the effect of inhibiting alpha(v)beta(3)/alpha(v)beta(5) integrins by cilengitide in experimentally induced breast cancer bone metastases using noninvasive imaging techniques. For this purpose, nude rats bearing established breast cancer bone metastases were treated with cilengitide, a small molecule inhibitor of alpha(v)beta(3) and alpha(v)beta(5) integrins (75 mg/kg, five days per week; n = 12 rats) and compared to vehicle-treated control rats (n = 12). In a longitudinal study, conventional magnetic resonance imaging (MRI) and flat panel volumetric computed tomography were used to assess the volume of the soft tissue tumor and osteolysis, respectively, and dynamic contrast-enhanced (DCE-) MRI was performed to determine functional parameters of the tumor vasculature reflecting blood volume and blood vessel permeability. In rats treated with cilengitide, VCT and MRI showed that osteolytic lesions and the respective bone metastatic soft tissue tumors progressed more slowly than in vehicle-treated controls. DCE-MRI indicated a decrease in blood volume and an increase in vessel permeability and immunohistology revealed increased numbers of immature vessels in cilengitide-treated rats compared to vehicle controls. In conclusion, treatment of experimental breast cancer bone metastases with cilengitide resulted in pronounced antiresorptive and antitumor effects, suggesting that alpha(v)beta(3)/alpha(v)beta(5) inhibition may be a promising therapeutic approach for bone metastases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available